Tsutani, Y.; Miyata, Y.; Suzuki, K.; Tanaka, F.; Ito, H.; Yamashita, Y.; Okada, M.
Pathologic Response and Survival after Neoadjuvant Chemotherapy with Bevacizumab Followed by Surgery for Clinical Stage II/IIIA Nonsquamous Non-Small-Cell Lung Cancer: Results from a Phase II Feasibility Study (NAVAL). Cancers 2024, 16, 2363.
https://doi.org/10.3390/cancers16132363
AMA Style
Tsutani Y, Miyata Y, Suzuki K, Tanaka F, Ito H, Yamashita Y, Okada M.
Pathologic Response and Survival after Neoadjuvant Chemotherapy with Bevacizumab Followed by Surgery for Clinical Stage II/IIIA Nonsquamous Non-Small-Cell Lung Cancer: Results from a Phase II Feasibility Study (NAVAL). Cancers. 2024; 16(13):2363.
https://doi.org/10.3390/cancers16132363
Chicago/Turabian Style
Tsutani, Yasuhiro, Yoshihiro Miyata, Kenji Suzuki, Fumihiro Tanaka, Hiroyuki Ito, Yoshinori Yamashita, and Morihito Okada.
2024. "Pathologic Response and Survival after Neoadjuvant Chemotherapy with Bevacizumab Followed by Surgery for Clinical Stage II/IIIA Nonsquamous Non-Small-Cell Lung Cancer: Results from a Phase II Feasibility Study (NAVAL)" Cancers 16, no. 13: 2363.
https://doi.org/10.3390/cancers16132363
APA Style
Tsutani, Y., Miyata, Y., Suzuki, K., Tanaka, F., Ito, H., Yamashita, Y., & Okada, M.
(2024). Pathologic Response and Survival after Neoadjuvant Chemotherapy with Bevacizumab Followed by Surgery for Clinical Stage II/IIIA Nonsquamous Non-Small-Cell Lung Cancer: Results from a Phase II Feasibility Study (NAVAL). Cancers, 16(13), 2363.
https://doi.org/10.3390/cancers16132363
